CD86 and cancer: The CTLA-4 co-inhibitory receptor is constitutively expressed on T cells and competes with CD28 co-stimulatory receptor for binding to their cognate ligands CD80 (B7.1) and CD86 (B7.2) on cancer cells, for which it has a greater affinity, thereby effectively inhibiting CTL activation [51,52].